The term “psilocybin resets the brain” frequently appears in the media and in personal stories. It sounds appealingly simple, especially for people living with the consequences of trauma and stuck patterns in thinking, feeling, and reacting. At the same time, “reset” is not an official medical term and can create a false impression, as if a single experience permanently restores the brain or life. In this article, we explain what researchers *do* mean by the reorganization of brain circuits through psilocybin, which mechanisms play a role in this process, and why context, guidance, and integration are so important.
What does “reorganizing brain circuits” mean in the context of trauma?
Trauma is often linked to long-term changes in stress responses, emotion regulation, and attention. This can manifest as flashbacks, hyperalertness, avoidance, or conversely, emotional numbness. Neurobiologically, the literature often discusses strong, ingrained networks that quickly “switch on” in response to triggers. Consider patterns in the interaction between areas involved in threat detection, memory, self-image, and meaning-making.
When researchers say that psilocybin “reorganizes” brain circuits, they usually refer to two levels. First: temporary changes in communication between brain networks during the experience. Secondly: a period of increased plasticity afterwards, in which new connections can form more easily and old patterns can become less dominant. This does not mean that trauma “disappears,” but it can explain why some people experience space to deal with memories, emotions, and beliefs differently.
From psilocybin to psilocin: the start of the cascade
Psilocybin is a prodrug. In the body, it is converted into psilocin, the substance that causes the majority of the psychoactive effects. Research focuses primarily on the binding of psilocin to serotonin receptors, in particular the 5‑HT2A-receptor in the cortex.
Activation of this receptor triggers a chain of signaling pathways involved in cellular adaptation, such as pathways often referred to as MAPK/ERK and mTOR. In animal and cell studies, these types of pathways are associated with processes such as gene expression and protein synthesis, which in turn are relevant to synaptic changes. It is important to add nuance: How exactly this translates into long-term psychological change in humans is not yet fully verifiable.. We see indications, but not hard, direct causality everywhere.
Neuroplasticity: why “new pathways” is more than a metaphor
An important part of the “reset” story is neuroplasticity. In preclinical studies, an increase in markers often linked to plasticity, such as BDNF-related signaling and changes in dendritic spines, has regularly been observed after the administration of psychedelics. Simply put: a window seems to open up in which the brain can learn and reorganize more quickly.
In the context of trauma, that concept is relevant because recovery often comes down to new associations and new regulation skills. For example: a trigger can initially automatically lead to panic, dissociation, or shame, and later to “I notice this and I can regulate myself.” Psilocybin may potentially support a phase in which such new connections become more ingrained, but this usually does not happen spontaneously. Guidance and integration help determine whether insights also take root in behavior and relationships.
Network Dynamics: Default Mode Network and “looser” self-narrative
In neuroimaging research, it is often described that psilocybin affects the cohesion within the Default Mode Network (DMN). temporarily decreases. The DMN is involved in, among other things, self-reflection, autobiographical memory, and the construction of an ongoing self-narrative. At the same time, an increase is regularly observed in global functional connectivity: networks that normally operate more separately are temporarily communicating more strongly with each other.
This often goes hand in hand with subjective experiences such as ego softening or ego dissolution: the feeling that you are less stuck in a rigid “I” and experience more space to observe, feel, and give meaning. For some people with trauma, this can provide temporary distance from automatic beliefs such as “I am unsafe” or “it is my fault.” For others, it can actually be intense, because control loosens. Therefore, it is important not to romanticize the “reset”: the same disruption that can provide flexibility can also be overwhelming without a proper foundation.
Course of time: acute, subacute and prolonged
Researchers often distinguish between three phases. In the acute phase (hours) the strong subjective effects take place, with altered perception, emotional breakthroughs, and a different experience of time and self. In the subacute phase (days) many participants report an “afterglow”: more openness, connectedness, or clarity. Increased plasticity is also often discussed during this period, although the exact duration has not been unequivocally established in humans.
The long-term phase (weeks to months) seems to be associated with lasting changes in perspective and behavior for a portion of people. At the same time, research also shows that not everyone experiences lasting improvement and that prevents relapse. This makes integration and appropriate support particularly important, especially in cases of trauma, where safety, boundaries, and stabilization are central.
Safety and harm reduction: what we can and cannot say
In controlled studies, psilocybin is generally well tolerated, but there are clear risks and contraindications. For instance, the use of psychedelics is often advised against in cases of (an increased risk of) psychosis or bipolar disorder. There are also concerns regarding cardiovascular strain, as heart rate and blood pressure may temporarily increase. Additionally, certain medications can influence the effects or alter the risks. This article does not provide individual medical advice; always discuss health questions with a qualified physician.
From a harm reduction perspective, “set & setting” are crucial: preparation, a safe environment, good support during the experience, and integration afterward. In research, psilocybin is not a standalone substance, but part of a protocol involving screening, guidance, and aftercare. This is partly why outcomes from studies cannot be directly translated to uncontrolled use.
How does this relate to MDMA and trauma work?
In scientific studies regarding trauma, MDMA is also being examined alongside psilocybin, primarily due to the specific emotional and relational effects being investigated in that context. It is important to remain factual: MDMA sessions can currently only be discussed within scientific research or in practice via harm reduction., and not as a standard treatment with a guaranteed outcome.
Those seeking orientation should distinguish between: (1) scientific findings, (2) anecdotal evidence, and (3) practical harm reduction information. An accessible starting point for reading more about the background and context is the source article on which this explanation is based: How does psilocybin reset the brain?.
Conclusion
Psilocybin does not “reset” the brain like an on-off switch, but research suggests it can temporarily loosen brain networks and support a period of increased plasticity. In relation to trauma, this could mean that rigid patterns are temporarily less dominant and that new meanings and regulatory strategies can take root better, especially with proper preparation and integration. At the same time, uncertainties remain regarding optimal dosage, timing, long-term effects, and for whom it is safe and appropriate.
Those who wish to explore guided sessions and harm reduction more broadly can find information via sign up for an MDMA session. This is intended as a practical entry point for discussion and alignment, not as a promise of a specific outcome.
English 
Dutch 
German 
French